Geron Corporation (Jobs) Shares Sink After Study Data Shows Little Effect On Malignant Cell Reproduction
Geron is testing some investors' patience. The California-based biotechnology company failed to deliver blockbuster news on its novel GRN163L cancer treatment during this week's Pan Pacific Lymphoma Conference in Hawaii. Instead, the company simply reported that GRN163L has "demonstrated good pharmacokinetics and tolerability" in patients tested during phase I/II studies so far.